Search Within

Ana Alarcon Tomas

Formats
  1. Meeting Abstract (28)
  2. Journal Article (22)
  3. Research Letter (2)
  4. Book Section (1)
  5. Correspondence (1)
  6. Review (1)
Groups
  1. Bone Marrow Transplant (55)
  2. Center for Hematologic Malignancies (55)
  3. Department of Medicine (55)
  4. Hematologic Malignancies, Division of (55)
  5. CTCR Scholars (45)
  6. Survivorship Research (45)

More Groups

People
  1. Miguel-Angel Perales (55)
  2. Gunjan Shah (45)
  3. Michael Scordo (43)
  4. Roni Shouval (41)
  5. Maria Palomba (39)
  6. Parastoo Dahi (39)

More People

Years
  1. 2025 (3)
  2. 2024 (5)
  3. 2023 (22)
  4. 2022 (13)
  5. 2021 (7)
  6. 2020 (3)

More Years

Publications
  1. Blood (20)
  2. Blood Advances (6)
  3. Bone Marrow Transplantation (6)
  4. Transplantation and Cellular Therapy (6)
  5. Haematologica (2)
  6. Hematological Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (26)
  2. Nature Publishing Group (10)
  3. Elsevier Inc. (9)
  4. Ferrata Storti Foundation (2)
  5. Wiley Blackwell (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
    Journal Article

    Wudhikarn, K.; Tomas, A. A.; Flynn, J. R.; Devlin, S. M.; Brower, J.; Bachanova, V.; Nastoupil, L. J.; McGuirk, J. P.; Maziarz, R. T.; Oluwole, O. O.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
    Journal Article

    Mahmood, S. S.; Riedell, P. A.; Feldman, S.; George, G.; Sansoterra, S. A.; Althaus, T.; Rehman, M.; Mead, E.; Liu, J. E.; Devereux, R. B.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
    Journal Article

    Zurko, J.; Ramdial, J.; Shadman, M.; Ahmed, S.; Szabo, A.; Iovino, L.; Tomas, A. A.; Sauter, C.; Perales, M. A.; Shah, N. N.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
    Journal Article

    Sanchez-Escamilla, M.; Flynn, J.; Devlin, S.; Maloy, M.; Fatmi, S. A.; Tomas, A. A.; Escribano-Serrat, S.; Ponce, D.; Sauter, C. S.; Giralt, S. A.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma
    Journal Article

    Fried, S.; Shouval, R.; Walji, M.; Flynn, J. R.; Yerushalmi, R.; Shem-Tov, N.; Danylesko, I.; Tomas, A. A.; Fein, J. A.; Devlin, S. M.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
    Journal Article

    Alarcon Tomas, A.; Fein, J. A.; Fried, S.; Flynn, J. R.; Devlin, S. M.; Fingrut, W. B.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; more...
    Leukemia (2023)

    Fulltext@MSK | Save